5 Reasons to Celebrate GT Biopharma’s Breakthrough And to Consider Investing Now

And this under-the-radar company has already experienced a 494.9% surge in share price, which is just the beginning of this remarkable story.

Research by Tim Collins and Bob Byrne of Streetlight Equity

April 14, 2021

Disrupter #1: This Revolutionary Cancer Breakthrough by Dr. Jeffrey Miller and the University of Minnesota team could change cancer treatment forever.

GT Biopharma’s breakthrough therapy represents the next generation in the war on cancer, and it’s already impressing the medical community with outstanding early results. Scientists spent more than 20 years to get this groundbreaking technology off the ground… But it wasn’t until just recently that an elite team of medical researchers, scientists, and oncologists at the University of Minnesota. TriKE™ is being hailed as the new “serial killer” treatment because it harnesses the power of your body’s NK (natural killer cells) in a way far superior to treatments currently being used. This revolutionary new therapy actually allows cancer patients to use their own immune system to target and kill cancer cells – and only cancer cells – again and again.

Disrupter #2: GT Biopharma’s Clinical Trial has already yielded impressive results

The company’s GTB-3550 TriKE™ clinical trial began in February 2020 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS). These are diseases that have been virtually impossible to treat effectively – until now. Stage 4 cancer patients have been enrolled in the company’s clinical trial…and to date, the results have been even better than expected, in some cases cancer proliferation by up to 63.7%, with no harmful side-effects.

Disrupter #3: GT Biopharma’s breakthrough appears to be far superior to other immune treatments

Early research in this field used what is called CAR-T therapy. This technology used genetically modified T-cells (a crucial part of your body’s immune system) to fight cancer.

  • No Stressful Conditioning Regiment – CAR-T cell therapy is often administered in conjunction with a stressful – even toxic – conditioning regimen that many patients find uncomfortable…and even impossible to manage.
  • No Geographical Limitations – CAR-T cell therapy is only available at specialized centers, and patients are required to stay within two miles of the center for the four-week treatment period. By contrast, NK Cell Therapy could have zero geographical limitations and could be administered as an outpatient therapy.
  • A Much Lower, Affordable Cost –CAR-T therapies led by companies such as Novartis, can come with staggering price tags as high as $750,000. This can obviously be cost prohibitive for many patients. And insurance companies don’t want to pay for it. NK Cell Therapies, comparatively, are projected to cost significantly less – in some cases as low as $30,000 – allowing for rapid adoption once approval is granted.

Disrupter #4: The company is moving quickly to position itself for short- and long-term success as GT Biopharma maximizes the potential for its TriKE™ technology.

The company recently entered into a strategic partnership with Cytovance Biologics, a USA-based development and manufacturing organization (CDMO). This agreement makes Cytovance the exclusive GMP manufacturer for three of GT Biopharma’s TriKE™ therapeutic product candidates. This is a potentially significant strategic partnership for the company and demonstrates that GT Biopharma (NASDAQ: GTBP) is moving quickly to position itself for successful rollout of its TriKE™ therapeutic products upon completion of its clinical trials. In addition, the company has already seen a significant growth in share price – climbing more than 494.9% from $0.079 on January 27, 2020 to $0.47 on January 27, 2021 and has recently up-listed to the Nasdaq in February 2021.

    Disrupter #5: We believe this company could be an acquisition target

    Every year, the big drug companies lose billions of dollars to generic versions. Thus, many of them are on the hunt for smaller companies to partner with that have done all the research on new drugs. As a result, we believe it’s a strong possibility that GT Biopharma (NASDAQ: GTBP) could be targeted for acquisition by any number of larger drug companies – which could put upward pressure on its stock price. We strongly urge you to consider discussing an investment into GT Biopharma (NASDAQ: GTBP) with your personal investment advisor. Streetlight Equity has the better part of a century’s experience in financial markets, with an expertise ranging from high-frequency trading and hedge fund management to geopolitical analysis and IPO consulting.

      The Streetlight Equity intelligence is clear: the biotech mania is just getting started.

      All you need to do it agree to take a no-risk look at our work at the Streetlight Equity and we’ll immediately send you a free copy of the special report we have prepared on this opportunity.

      We are a group of influential, highly placed investment professionals with the better part of a century’s experience, working for the most powerful and largest research investment companies in the world.

      Our expertise includes stock investments, hedge funds, money management, private companies and much more. As seasoned stock market traders and analysts, we use a combination of technical, fundamental and risk analysis to identify and share ideas.

      Now, because this potential profit opportunity with GT Biopharma is so exciting, we’re slashing the trial annual subscription fee.

      Through this special offer only, you can grab a 100% risk free, one-year trial for just $39.

      It’s risk free because, if you don’t like what you see once you’ve signed up, you can cancel within 30 days for a full refund.

      Regardless, you’ll immediately get the free report detailing more of this revolutionary new cancer therapy without chemo, radiation, or surgery, plus two extra free reports.

      3 Stocks Potentially Set to Skyrocket 300% or More

      FREE Bonus Report #1: 3 Stocks Potentially Set To Skyrocket to 300% or More (a $19.80 value)

      Here’s everything you need to know about possibly the three most exciting companies publicly trading. One is the world’s largest independent sell-side platform for every channel and format of streaming content! One is a true turnaround story. And one is the embodiment of artificial intelligence.

      wo Ways to Make More Profits With Rebalancing Your Portfolio

      FREE Bonus Report #2: Two Ways to Make More Profits Rebalancing Your Portfolio (a $19.80 value)

      For decades now, investors have been led to believe that a once-a year rebalancing of their portfolio is the best way to stay diversified, while ensuring that you buy low and sell high. But there’s a flaw in this calendar-based method and it’s likely costing you thousands of dollars. Fortunately, there’s a better way that keeps that money in your pocket where it belongs — and can even help you recoup some of your past losses.

      Subscribe Now

      For A Limited Time Only!

      There are an additional two reports – bringing your free reports to a total of 5 – if you test drive a 100% risk-free, 1-year platinum membership trial subscription for just $77. That’s nearly half of a 2-year subscription to The Wall Street Journal!

      4 Steps to Trade Like a Pro

      FREE 2-Year Bonus Report: 4 Steps to Trade Like a Pro (a $19.80 value)

      While most gambling involves simple chance, poker requires strategic thinking, calculated risk taking and an ability to read the table. In those respects, it’s not much different from investing. You have to know where to place your investment bets to minimize your risk while still giving yourself a shot at making some nice returns. In this special report, you’ll discover how getting better at poker — even if it’s playing for nickels and dimes — can make you a better, more profitable investor.

      2 Little Known Microcap Stocks Poised to Explode in 2021

      FREE 2-Year Bonus Report: 2 Little Known Microcap Stocks Poised to Explode in 2021 (a $19.80 value)

      Changing the world one gene and one sporting minute at a time could make these two stocks game changers for savvy investors. Find out the details of how these companies are quietly revolutionizing their respective industries and why you could be rewarded for paying attention.

      Subscribe Now

      You’re Fully Protected by the Streetlight Equity’s Money Back Double Guarantee

      1. You must be delighted with the ideas, strategies and financial market coverage you find at the Streetlight Equity. If not, or if you’re unhappy for any reason whatsoever, simply let unsubscribe within 30 days and get a 100% refund of every penny you paid with no questions asked.
      2. And you may keep the FREE special reports and any issues you have received for your trouble.

      If you cancel after 30 days, you’ll receive a prorated refund for the remaining balance of your subscription. And again, you may keep all the reports and issues you have received. To subscribe click here.

      Or for faster service and if you have any questions, call Toll-Free 1-888-638-8017 (24 hours a day/seven days a week).

      Subscribe Now

      Research by Tim Collins and Bob Byrne of Streetlight Equity

      April 14, 2021

      Become a Streetlight Equity Insider
      IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. Streetlight Equity is the publisher of these materials and is not responsible for errors and omissions. This publication is intended solely for information and educational purposes and is not to be construed, under any circumstances, as an offer to buy or sell, or a solicitation to buy or sell or trade, or as a personal recommendation to buy or sell or trade in any securities or commodities named in these materials. These materials are a paid advertisement.  Information gathered to create these materials is from sources believed to be reliable, but we cannot guarantee its reliability.  Furthermore, there are no assurances that you will profit or that any losses can or will be limited. It is important to know that no guarantee of any kind is implied or possible where projections of future conditions in the markets are attempted. Hypothetical or simulated performance results have certain inherent limitations as to liquidity and execution, among other variables. All readers should consult their own personal investment adviser before making an investment decision. Investing in securities is highly speculative and carries a great deal of risk, especially as to newer companies with comparatively short operating histories and limited earnings.  This report contains projections regarding future operating results, which are forward-looking statements. Those projections were derived from sources that have not been verified independently. All forward-looking statements are believed to have a reasonable basis, but are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Those projections should not be considered a comprehensive representation of the featured company’s future performance.  Streetlight Equity is a paid circulation newsletter and is not a financial analyst, investment advisor or broker/dealer. These materials are a solicitation for subscriptions for the newsletter and a paid promotional advertisement of GT Biopharma Inc. (NASDAQ: GTBP).  Streetlight Equity expects to generate new subscriber revenue as a result of this advertisement. This paid advertisement includes a stock profile of GT Biopharma Inc. (GTBP or the “Company”). Streetlight Equity is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to buy or sell, or as a solicitation to buy or sell, any securities.  Streetlight Equity assumes no obligation to provide any future views in support of the highlighted company.  In an effort to enhance public awareness of GTBP and its securities, GT Biopharma Inc. provided advertising agencies with a total budget of approximately $2,213,403 to cover the costs associated with creating, printing and distribution of this advertisement and other elements of this campaign in an effort to build investor awareness. GT Biopharma Inc. has represented to advertising agencies in writing that it is the source of all funds that have been or will be paid to advertising agencies for this advertising campaign. Streetlight Equity may generate new subscription revenue, the amount of which is unknown at this time, as a result of the distribution of these materials. The advertising agencies involved in this campaign relied on information provided by GT Biopharma Inc. The advertising agencies will retain as their compensation any excess sums after all expenses are paid. GT Biopharma Inc. has represented to Streetlight Equity and the advertising agencies in writing that (1) its officers, directors, and principals (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) are beneficial owners of GT Biopharma Inc.; (2) the Issuer and its officers, directors, and principals will abide by the Issuer’s corporate governance and trading policies along with SEC and NASDAQ trading policies. If successful, this advertisement will increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of GTBP, increased trading volume, and possibly an increased share price of GTBP’s securities, which may be temporary. This advertisement, the advertising agencies and Streetlight Equity do not purport to provide a complete analysis of GTBP’s financial position, operations, or prospects, and this is not to be construed as a recommendation by Streetlight Equity as an offer to buy or sell any security or as investment advice. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell and only after reviewing the financial statements and other pertinent publicly-available information about GTBP and its industry. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in GTBP’s SEC filings. Investing in securities, such as GTBP, is inherently speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Streetlight Equity cannot guarantee the accuracy or completeness of this information. The advertising agencies and Streetlight Equity note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect GTBP’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for GTBP’s products and/or services, GT Biopharma Inc.’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. Streetlight Equity is the publisher’s trademark. All trademarks used in this advertisement other than Streetlight Equity are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Streetlight Equity are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks. More information can be found on the GT Biopharma Inc. website (gtbiopharma.com). As with any low-priced stock, investors should use only risk capital they are willing to lose or hold for long-term investing.